Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ULREA-PVS-NP in Retinitis Pigmentosa
NCT07774975Phase 1Recruiting
- Sponsor
- Kyushu University
- Start
- Oct 2026
- Primary completion
- Jan 2028
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of ULREA-PVS-NP in retinitis pigmentosa (RP), sponsored by Kyushu University. Primary endpoint: Incidence of adverse events at 84 days. Started Oct 2026; status: recruiting.
02
Drugs
ULREA-PVS-NP
03
Conditions
retinitis pigmentosa (RP)
Beyond the preview
Go deeper on NCT07774975.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07774975.